Our in vitro biology team has in-depth knowledge of different therapeutic areas and target classes. De novo assay development without any literature precedence for novel target classes or therapeutic indications along with assay customization has added significant value to our Integrated Drug Discovery (IDD) projects and driven compound progression and clinical candidate nomination successfully.
Our offerings include screening and profiling services/platforms under different therapeutic areas and target classes.
In vitro Assay Capabilities
A platform for screening of NCEs and NBEs against major therapeutic target classes: GPCRs, ion channels, proteases, other hydrolytic enzymes, and membrane receptors are a few examples of our experience in target classes.
APSL focuses and caters to a wide range of therapeutic areas like asthma and COPD, metabolic disorders (diabetes, NASH & obesity), inflammation, oncology, immunology, stem cell biology, osteoporosis, angiogenesis, CNS, and pain. We also have experience in epigenetics and Protein-Protein Interaction (PPI) targets. At APSL, we are continuously adding the experience of advanced and emerging drug classes. Examples include PROTAC, Oligonucleotide, ADC, and mRNA. We offer a complete set of bioassays for PROTAC discovery.
In vitro Assay Development
- Phenotypic Assays: Phenotypic assays aim to identify the molecules which can alter a cell's phenotype. Here, we look at the effect of a substance on the entire biological system as opposed to an isolated component of it. Phenotypic Assays are the most refined and delicate of all assays and can be performed in cells, such as stem-cell-derived human cells, isolated tissues, or entire organisms.
- Mechanistic Assays: We have the core expertise for the level of mechanistic understanding required for drug discovery. Mechanistic assays are an important part of in vitro service portfolio, as they provide further information about the cell mechanism displayed by the study compound. All assays are with fluorescence or luminescence endpoints.
- Cell-based Assays: To understand the correlation of networks in a complex biological system, we can design custom cell-based assays that cater to every stage of drug development. As a leading CDMO company and Contract research organization, we have at our disposal a wide range of cell types which in combination with innovative technologies result in assays with improved translational success.
- Readout Platforms: We offer diverse readout platforms such as Luminescence, Fluorescence (FRET, TR-FRET), Fluorescence Polarization (FP), AlphaLISA, AlphaScreen, Absorbance, and UV to NIR.
In vitro Assay Capability Range
- Functional Assay
- Cell Viability
- Apoptosis
- Invasion
- Migration
- Cell Senescence
- Cell Cycle Analysis
- Necroptosis Assay
- Pyroptosis Assay
- Specialized Assays
- Target engagement assays via Nano-BRET/ CESTA
- 3D cells co-culture
- Spheroid culture
- Organoid culture
- Stem cell-derived functional cells – Hepatocytes, Cardiac, etc
- Immunological Assays
- Dendritic cell
- T-cell cytotoxicity
- Treg – Immune suppression
- Immune cell profiling
- Mixed lymphocyte
- Biomarker Assay
- Cytokine modulation
- Target gene expression
- Phosphorylation of signaling intermediates
- Cytokine-induced transcription factor phosphorylation
Why Aurigene Pharmaceutical Services?
Complex and specialized assay development
High throughput expression system
Functional, Mechanism of Action (MoA) and target engagement studies
Expertise to support Integrated Drug Discovery programs
Deep therapeutic insights and state-of-the-art facilities
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
FEBRUARY 25, 2025
Transforming Drug Discovery with Aurigene.AI
In the early 2000s, developing Sovaldi, a hepatitis C treatment, took over a decade and nearly $2 billion. Similarly, Zolgensma, a gene therapy for spinal muscular atrophy, required 15 years due to its complexity. However, the advent of artificial intelligence (AI) has revolutionized drug discovery. For example, in 2022, Pfizer's PAXLOVID, an oral COVID...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Familiarization, process optimization, and cGMP manufacturing and supply of 30.0 kg of a Bioactive Nucleotide (NAD Booster)
Background: A US-based biopharmaceutical company approached Aurigene Pharmaceutical Services for the familiarization, process development, and cGMP manufacturing and supply of 30.0 kg Nucleotide product (NAD booster) for phase-appropriate studies. The synthesis of the desired product involves three linear stages, which starts with reaction of a pentose...
Read More
Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques
2022
Objective of the manuscript is to identify the degradants observed in the thermal and oxidation degradation sample of Empagliflozin and Linagliptin tablets by using LC-MS and HPLC-PDA instrumental techniques. Thermal and oxidation degradation samples were injected in HPLC-PDA and LC-MS instruments. Mass of the degradants were detected by LC-MS technique, ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market